Clearside Biomedical announces approval of XIPERE in Canada
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 23 2025
0mins
Health Canada Approval: Clearside Biomedical has received approval from Health Canada for XIPERE, which is used for suprachoroidal treatment of uveitic macular edema (UME).
Global Availability: XIPERE is already approved in the United States, Canada, Australia, and Singapore, and is currently under regulatory review in China.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
